A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo

Figure 1 Clone of flk-1-domain1-3 and construction of ex-pressing vector. A: DNA marker; B: PCR results.

Figure 2 Functionality of the flk-1-domain 1-3 expressing vector. A: Western blotting of protein extracted from COS7 cell; B: Western blotting of protein from COS7 transfected with vaccine; C: Western blotting of protein from COS7 transfected with pcDNA3.1 (+).

Figure 3 COS 7 cell before and after transfection with vaccine, plasmid and saline, respectively. A, D: One day before and 2 wk after transfection with vaccine; B, E: One day before and 2 wk after transfection with plasmid; C, F: One day before and 2 wk after transfection with saline.

Figure 4 CTL activity of each group at different effector/target rate.

Figure 5 Curve of tumor growth in preventive group.

Figure 6 Microvessel staining by anti-CD31 antibody in preventive Group (Original magnification: × 200). A: Vaccine subgroup; B: Plasmid control group; C: Saline control group.

Figure 7 Curve of tumor growth in therapeutic group.

Figure 8 Microvessel staining by anti-CD31 antibody in therapeutic group. A: Vaccine subgroup; B: Plasmid control group; C: Saline control group.